Dr. John Leonard on Top Lymphoma Studies at the 2015 ASH Annual Meeting
Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease
John Leonard, MD, medical oncologist, Weill Cornell Medicine and NewYorkPresbyterian Hospital , discusses the top lymphoma studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting. Leonard says some of the more interesting studies to crop up in the field of Hodgkin's lymphoma include ones that utilize checkpoint inhibitors, as well as one of the first combination immunotherapies to be used in the disease a duet of brentuximab vedotin and ipilimumab.
Leonard goes on to say there is more data that involves brentuximab alongside chemotherapy in elderly patients, which would be in place of ABVD chemotherapy. ABVD chemotherapy is a standard of care for older patients with Hodgkin's lymphoma, though the treatment has proven less effective and more toxic to patients over time.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Challenges for Non–CAR T-Cell Treatment of Early Relapsed DLBCL
April 18th 2024During a Case-Based Roundtable® event, Elizabeth A. Brém, MD, discussed treatment approaches for a patient with early relapsed or primary refractory diffuse large B-cell lymphoma in the first article of a 2-part series.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
